Hepatitis C in dialysis units: the Saudi experience.
Hepatitis C virus (HCV) infection is a significant health problem, as it can lead to chronic active hepatitis, liver cirrhosis, and hepatic carcinoma. Patients undergoing hemodialysis treatment are at increased risk of contracting HCV and other viral infections. This is primarily due to their impaired cellular immunity, underlying diseases, and blood exposure for a prolonged period. Transmission of viral hepatitis, and in particular HCV in dialysis units, has been showing a progressive increase worldwide, ranging between 5% in some western countries and up to 70% in some developing countries. The annual rate of HCV seroconversion in Saudi Arabia is 7% to 9%, while its prevalence is variable between 15% and 80%. This prevalence remained at almost 50% in recent years, despite the further increase in number of patients with end-stage renal disease and the expansion of dialysis services. The most prevalent genotypes in Saudi Arabia are genotype 4 followed by genotypes 1a and 1b, whereas genotypes 2a/2b, 3, 5, and 6 are rare. Genotypes 1 and 4 were associated with different histological grades of liver disease. Mixed infections with more than one genotype were observed in some studies. Isolation of dialysis machines and infected patients, together with strict application of infection-control policies and procedures and continuous education and training of nursing staff, remain the cornerstone in prevention and control of the spread of HCV infection in dialysis units. Interferon (INF)-alpha or pegylated INF, alone or in combination with ribavirin, have shown great promise in the treatment of chronic HCV in dialysis patients.
Karkar
Ayman
A
Department of Nephrology, Kanoo Kidney Centre, Dammam Central Hospital, Dammam, Saudi Arabia. aymankarkar@yahoo.com
D000998:Antiviral Agents / Q000627:therapeutic use; D004509:Education, Nursing, Continuing; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics / Q000276:immunology; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000453:epidemiology* / Q000235:genetics / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D017053:Infection Control; D016898:Interferon-alpha / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications / Q000276:immunology / Q000628:therapy / Q000821:virology; D015995:Prevalence; D006435:Renal Dialysis / Q000009:adverse effects; D012254:Ribavirin / Q000627:therapeutic use; D012529:Saudi Arabia
D000998:Antiviral Agents; D016898:Interferon-alpha; D012254:Ribavirin